Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunological Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients

NCT04723706 is registered in ClinicalTrials.gov with Henry Ford Health System as lead sponsor.

NCT NCT04723706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04723706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunological Response to SARS-CoV-2 Vaccine in Stem Cell Transplant and Cellular Therapy Patients
Lead sponsor
Henry Ford Health System
Phase
Observational
Overall status
Completed
Start date
March 19, 2021
Completion date
January 2, 2024
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic disorders and bone marrow failure, hematopoietic stem cell transplantation (hsct) or cellular therapy (cart)